The innovative approach involves the manipulation of light to interact with hydrogels, a versatile material often used in 3D bioprinting. By refining the properties of light, the researchers succeeded in altering the internal structure of these hydrogels to guide the behavior and growth patterns of cells embedded within. This cutting-edge method addresses long-standing challenges in recapitulating the complex environments of human tissues, paving the way for more effective therapies aimed at repairing damaged organs and tissues.

Dr. Johnson V. John, the lead investigator of the study, expressed the potential of their technique in revolutionizing how microtissues are created. “Our method allows for the fabrication of microtissue with highly precise structural qualities,” Dr. John stated, emphasizing the technique’s importance in shaping engineered tissues such as muscle and retinal structures. By introducing this novel class of biomaterials, the research team is setting the stage for a new wave of tissue engineering that can actively facilitate the formation of viable tissues through a bottom-up approach.

The applications of these microgels are manifold, as shown in experiments where muscle cells were integrated into rod-shaped gels. This configuration not only aided the alignment of muscle cells but also encouraged the formation of muscle fibers. Such progress is particularly encouraging for developing injectable treatments aimed at repairing muscle injuries, which could potentially transform rehabilitation processes for patients with muscle damage.

Furthermore, the research team demonstrated the versatility of their microgels by utilizing them to hold photoreceptor cells, which autonomously organized into structures resembling the outer layers of the retina. This discovery has sweeping implications for future therapies targeting retinal diseases that impact vision, showcasing how the aligning of cells can lead to functionalities traditionally found in biological tissues. The integration of angiogenic peptides within these microgels further promotes the development of new blood vessels, thereby enhancing both in vitro and in vivo tissue engineering outcomes.

Key to the success of this research is the ability of the microgels to retain their form during the injection process. This stability ensures that the materials can effectively support not only cell growth but also facilitate new blood vessel formation, which is critical for tissue development and repair. The flexible design framework of these microgels allows for customization across various clinical applications, making them a promising tool in the realms of wound healing, organ repair, and disease study.

Dr. Ali Khademhosseini, the CEO of TIBI, praised the research, noting its potential to bridge significant gaps in conventional medical practices. “This research marks a monumental advancement in our quest to create structures that can develop into functional tissues,” Dr. Khademhosseini reflected. By fusing light-based fabrication techniques with sophisticated biomaterials, TIBI is edging closer to realizing minimally invasive, personalized therapeutic options that could revolutionize patient care.

The impact of this study is underscored by the support it received from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and TIBI itself. The collaboration reflects a concerted effort to push boundaries in biomedical innovation and establish effective treatments grounded in cutting-edge scientific research. With potential applications extending far beyond traditional uses, the implications of this work are profound.

The use of light-based technologies in bioprinting ensures that finer control can be maintained over cellular environments, a crucial factor in replicating the natural structural complexities experienced within biological tissues. The study paves the way for future exploration into more adaptive materials for tissue engineering, where dynamic properties can enhance recovery processes post-treatment.

As the medical field advocates for advancements in personalized medicine, the findings presented in this research represent a compelling leap towards integrating sophisticated materials with patient-specific solutions. By continuously refining and innovating these strategies, the Terasaki Institute is positioning itself at the forefront of a transformative era in tissue engineering and biomedical research.

As researchers continue to explore the macro- and micro-level intricacies of tissue formation and functionality, the potential of intelligently designed biomaterials to revolutionize medical treatments remains a primary focus. This study not only enriches the scientific landscape with new methodologies but also lays the groundwork for future innovations in organ regeneration and tissue repair strategies, potentially offering solutions to pressing health challenges faced by millions worldwide.

In conclusion, this research embodies the interplay between engineering, biology, and medicine, a synergy that is essential as we strive toward innovative solutions in healthcare. The Terasaki Institute’s dedication to advancing biomedical innovations through rigorous research is set to shape the future of therapeutic interventions, providing a beacon of hope for many in need of advanced regenerative treatments.

—

Subject of Research: Not applicable
Article Title: Filamented Light (FLight) Biofabrication of Aligned Fibrillar Structures to Direct 3D Cell Organization Within Microgels
News Publication Date: 10-May-2025
Web References: http://dx.doi.org/10.1002/smll.202500261
References: Not applicable
Image Credits: Terasaki Institute

Keywords

Tissue engineering, 3D bioprinting, microgels, cell organization, biomedical innovation, regenerative medicine, personalized therapy, light-based fabrication.

One of the long-standing challenges in hepatology and tissue engineering has been the liver’s exceptional complexity. Unlike many organs, the liver performs a vast repertoire of bioactive and metabolic processes, from glucose regulation to bile acid secretion. Replicating this multifaceted functionality in vitro has been hindered by the liver’s demanding energy requirements and the difficulty of sustaining hepatocyte function. Typically, isolated hepatocytes undergo phenotypic changes rapidly when cultured, often transdifferentiating into cholangiocyte-like cells that line bile ducts, resulting in loss of the hepatocyte’s intrinsic metabolic capabilities within one to two weeks.

The innovative research team, led by Ryo Igarashi and Mayumi Oda, overcame this barrier by utilizing cryopreserved adult human hepatocytes sourced directly from patients. Their pivotal discovery centered on the application of oncostatin M, a cytokine involved in inflammatory signaling pathways that had not previously been leveraged in organoid culture systems. Treatment with oncostatin M triggered an extraordinary proliferation phase, achieving a million-fold expansion in organoid numbers. This unprecedented growth contrasts starkly with previous methodologies, which struggled to maintain viable hepatocyte populations beyond short timeframes.

Extended cultivation saw these hepatocyte organoids maintain their viability and proliferative capacity for over three months, surviving up to six months without losing the potential to differentiate. This longevity is critical, as it allows researchers to conduct extended functional studies and disease modeling that were previously impossible due to rapid cell decline. The team also pioneered a chemically-defined hormonal differentiation protocol that stimulates hepatocyte maturation. Post differentiation, the organoids began expressing key liver functions, including the synthesis and secretion of glucose, urea, cholesterol, triglycerides, and bile acids—broadcasting a level of metabolic activity comparable to in vivo human hepatocytes.

Particularly notable was the organoids’ formation of bile canaliculi-like networks—microscopic tubular structures that enable the transport of bile acids—mimicking the liver’s native architecture. This functionality is essential for modeling hepatobiliary diseases and evaluating drugs that target bile acid metabolism. Levels of albumin secretion, an essential plasma protein responsible for maintaining oncotic pressure and transporting various substances, not only matched but surpassed those reported in existing hepatocyte culture systems.

The identification of oncostatin M as a key modulator of hepatocyte proliferation represents more than just a technical milestone; it uncovers new molecular underpinnings of liver biology. According to senior researcher Toshiro Sato, this discovery expands the compendium of factors capable of ‘unlocking’ the regenerative and differentiation potential of adult liver cells. Previously, only a handful of molecules were known to induce organoid growth, but oncostatin M provides a novel avenue for the creation of diverse, functional liver tissue models.

The translation of this technology into preclinical models further demonstrated its therapeutic promise. When transplanted into immunocompromised mice with impaired liver function, the human hepatocyte organoids engrafted successfully, replacing lost liver cells and restoring fundamental liver functionalities. This achievement addresses the critical bottleneck in liver transplantation—the scarcity and fragility of donor organs. Unlike donated whole organs that must be transplanted rapidly post-harvest, hepatocyte organoids derived from frozen cells can potentially be expanded on demand, circumventing logistical and preservation challenges.

Moreover, this method may revolutionize regenerative therapies by enabling the generation of large quantities of functional liver tissue. Sato emphasizes that scaling up organoid proliferation to match the size and metabolic demand of a human liver remains a formidable hurdle but one with transformative potential. Should this be realized, it could redefine transplantation medicine, offering new lifelines to patients suffering from end-stage liver disease or genetic hepatic disorders.

Beyond transplantation, the hepatocyte organoids hold immense promise for pharmaceutical research. Traditional drug toxicity assessments rely on freshly isolated human hepatocytes, which lose functionality rapidly and vary considerably between batches. This variability complicates the development pipeline and inflates costs due to inconsistent experimental outcomes. In contrast, organoids provide a renewable, consistent source of metabolically active human liver cells, enabling more reliable drug screening, especially for hepatotoxic compounds.

The organoids have also proven superior in disease modeling. For example, they intrinsically synthesized lipids and, upon administration of therapeutic agents targeting metabolic-associated steatotic liver disease (MASLD), these lipid stores diminished accordingly. This contrasts with previous studies that introduced lipids artificially, offering less physiologically relevant models. Moreover, the team successfully employed gene-editing techniques to replicate pathological states such as ornithine transcarbamylase (OTC) deficiency—a rare, inherited disorder disrupting the urea cycle—thereby modeling genetic liver diseases with unprecedented fidelity.

Looking forward, researchers recognize the importance of enhancing organoid complexity. Incorporating additional liver cell types, such as Kupffer cells (resident macrophages), liver sinusoidal endothelial cells, and hepatic stellate cells, is vital to recapitulate the full cellular interplay that underpins liver physiology and immune responses. Furthermore, intensifying proliferative capacity beyond current levels remains a priority to meet the substantial cellular quantities demanded in clinical applications.

In sum, this innovative study represents a significant stride toward mimicking the human liver’s complexity in a laboratory platform. By integrating novel cytokine signaling pathways, advanced differentiation protocols, and precise gene editing, the researchers at Keio University have opened new horizons in personalized medicine, drug discovery, and regenerative therapies. As liver diseases continue to impose a global health burden, such cutting-edge organoid models may soon become indispensable tools in both basic science and translational medicine.

Subject of Research: Cells
Article Title: Generation of human adult hepatocyte organoids with metabolic functions
News Publication Date: April 16, 2025
Web References: http://dx.doi.org/10.1038/s41586-025-08861-y
Image Credits: Toshiro Sato from Keio University
Keywords: hepatocyte organoids, liver regeneration, oncostatin M, organoid proliferation, metabolic functions, liver disease modeling, MASLD, gene editing, urea cycle disorder, transplantation, regenerative medicine